Protagonist Therapeutics, Inc.
PTGX
Ранг среди акций
#2248
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to... Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.
Цена акции
$138.50
Последняя синхронизация: 2026-10-20
Рыночная капитализация
$8.96B
Изменение (1 день)
3.02%
Изменение (1 год)
84.67%
Страна
US
Торговля Protagonist Therapeutics, Inc. (PTGX)
Категория
Healthcare
История дроблений акций Protagonist Therapeutics, Inc. (PTGX)
Акции Protagonist Therapeutics, Inc. (символ: PTGX) прошли через 0 дроблений.
Последнее дробление произошло Oct 21, 2026.
Одна акция PTGX, купленная до Oct 21, 2026, сейчас соответствует 0 акциям PTGX.
Последнее дробление произошло Oct 21, 2026.
Одна акция PTGX, купленная до Oct 21, 2026, сейчас соответствует 0 акциям PTGX.
Список дроблений акций
| Год | Дробление | Коэффициент | Суммарный коэффициент |
|---|---|---|---|
| Недостаточно данных для указанных дат. | |||
Дробления акций аналогичных компаний или конкурентов
| Компания | Количество дроблений акций | Суммарный коэффициент | Страна |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
